色素異常症治療市場：疾患タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別

色素異常症治療の世界市場は、2025年には80億1,000万米ドルと推定され、2032年までには149億4,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR9.3％で成長すると予測されます。

図.色素異常症治療市場シェア（%）、地域別（2025年）

色素異常症とは、通常メラニンの過剰または不均一な分布に起因する皮膚の色の変化を特徴とする状態を指します。世界の色素異常症治療市場は、肝斑、白斑、炎症後色素沈着などの有病率の上昇により、ここ数年で大きく成長しています。色素沈着治療の選択肢に関する認知度の向上、こうした疾患に罹患しやすい高齢化人口の増加、先進的治療薬の継続的な発売など、さまざまな要因が市場拡大に拍車をかけています。しかし、洗練された治療にかかる高額な費用、特定の薬剤に伴うリスクや副作用は、依然として市場の大きな課題となっています。

市場力学：

世界の色素異常症治療市場は、主に遺伝的素因と生活習慣の変化による世界の色素沈着症の有病率の増加によって牽引されています。最近の推計によると、世界人口の1%から2%近くが白斑を患っており、肝斑の有病率は4%から10%です。このような皮膚疾患に罹患しやすい高齢者人口の増加も、大きな影響を与える要因となっています。さらに、バイオシミラーの参入とともに、副作用の少ない新しい外用薬や経口薬が開発され続けていることも、この分野に大きなチャンスをもたらしています。しかし、メラニン生成阻害剤の承認に関する厳しい規制、社会的タブーによる美容整形への消極的な姿勢、特に新興国における高額な費用など、特定の要因によって市場の成長が妨げられる可能性があります。

本調査の主な特徴

• 本レポートでは、世界の色素異常症治療市場を詳細に分析し、2024年を基準年とした予測期間（2025年～2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいて、世界の色素異常症治療市場における主要企業プロファイルを掲載しています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の色素異常症治療市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の色素異常症治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 主な発展
• 規制シナリオ
• パイプライン分析
• 疫学
• 価格設定とブランド分析
• メーカー収益
• 買収と提携のシナリオ
• 製品の発売/承認
• 資金調達と投資
• PEST分析
• ポーター分析

第4章 世界の色素異常症治療市場 - コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界の色素異常症治療市場、疾患タイプ別、2020年～2032年

• 肝斑
• 白斑
• アルビノ
• 炎症後色素沈着（PIH）
• その他

第6章 世界の色素異常症治療市場、薬剤タイプ別、2020年～2032年

• コルチコステロイド
• カルシニューリン阻害剤
• ヤヌスキナーゼ（JAK）阻害剤
• メラニン合成阻害剤
• その他

第7章 世界の色素異常症治療市場、投与経路別、2020年～2032年

• 経口
• 局所
• その他

第8章 世界の色素異常症治療市場、流通チャネル別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第9章 世界の色素異常症治療市場、地域別、2020年～2032年

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第10章 競合情勢

• 企業プロファイル
  • Abbvie Inc.
  • Edesa Biotech, Inc.
  • Amgen, Inc.
  • Pfizer Inc.
  • CLINUVEL PHARMACEUTICALS LTD
  • Uniza Group
  • Dr. Reddy's Laboratories Ltd.
  • Roivant Sciences Ltd.
  • Incyte
  • Aclaris Therapeutics, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • GSK plc.
  • Vyne Therapeutics Inc.
  • Temprian Therapeutics Inc.
  • Arrien Pharmaceuticals, LLC

第11章 アナリストの視点

• 運命の輪
• アナリストの見解
• Coherent Opportunity Map

第12章 参考文献と調査手法

• 参考文献
• 調査手法

Global Pigmentation Disorders Treatment Market is estimated to be valued at USD 8.01 Bn in 2025 and is expected to reach USD 14.94 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.3% from 2025 to 2032.

Figure. Pigmentation Disorders Treatment Market Share (%), By Region 2025

Pigmentation disorders refer to conditions characterized by changes in skin color that are usually caused due to excess or uneven distribution of melanin. The global pigmentation disorders treatment market has been growing significantly over the recent past owing to the rising prevalence of conditions like melasma, vitiligo, and post-inflammatory hyperpigmentation. Various factors such as increasing awareness regarding pigmentation treatment options, growing aging population vulnerable to such disorders, and continual launch of advanced therapeutics are fueling the market expansion. However, high cost of sophisticated treatments, risks and side effects associated with certain medications remain major challenges for the market.

Market Dynamics:

The global pigmentation disorders treatment market is primarily driven by the increasing prevalence of pigmentation disorders worldwide due to genetic predisposition as well as changes in lifestyle habits. According to recent estimates, nearly 1-2% of global population suffers from vitiligo while prevalence of melasma ranges between 4-10%. Growing geriatric population also prone to such skin conditions acts as a high-impact driver. Moreover, continual development of newer topical and oral medications with fewer side effects along with entry of biosimilars is creating ample opportunities in this space. However, the market growth can be hampered by certain factors including stringent regulations for approval of melanogenesis inhibitors, reluctance towards cosmetic procedures due to social taboo, and high costs involved particularly in emerging nations.

Key Features of the Study:

• This report provides in-depth analysis of the global pigmentation disorders treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global pigmentation disorders treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study Abbvie Inc., Edesa Biotech, Inc., Amgen, Inc., Pfizer Inc., CLINUVEL PHARMACEUTICALS LTD, Uniza Group, Dr. Reddy's Laboratories Ltd., Roivant Sciences Ltd., Incyte, Aclaris Therapeutics, Inc., Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., GSK plc., Vyne Therapeutics Inc., Temprian Therapeutics Inc., Arrien Pharmaceuticals, LLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global pigmentation disorders treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pigmentation disorders treatment market.

Detailed Segmentation-

• By Disorder Type:
  • Melasma
  • Vitiligo
  • Albinism
  • Post-Inflammatory Hyperpigmentation (PIH)
  • Others
• By Drug Type:
  • Corticosteroids
  • Calcineurin Inhibitors
  • Janus kinase (JAK) inhibitor
  • Melanin Synthesis Inhibitor
  • Others
• By Route of Administration:
  • Oral
  • Topical
  • Other
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles
  • Abbvie Inc.
  • Edesa Biotech, Inc.
  • Amgen, Inc.
  • Pfizer Inc.
  • CLINUVEL PHARMACEUTICALS LTD
  • Uniza Group
  • Reddy's Laboratories Ltd.
  • Roivant Sciences Ltd.
  • Incyte
  • Aclaris Therapeutics, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • GSK plc.
  • Vyne Therapeutics Inc.
  • Temprian Therapeutics Inc.
  • Arrien Pharmaceuticals, LLC

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Disorder Type
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Pipeline Analysis
• Epidemiology
• Pricing and Brand Analysis
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Pigmentation Disorders Treatment Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Pigmentation Disorders Treatment Market, By Disorder Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Melasma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Vitiligo
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Albinism
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Post-Inflammatory Hyperpigmentation (PIH)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Pigmentation Disorders Treatment Market, By Drug Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Calcineurin Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Janus kinase (JAK) inhibitor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Melanin Synthesis Inhibitor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Pigmentation Disorders Treatment Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Topical
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Pigmentation Disorders Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Pigmentation Disorders Treatment Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

• Company Profiles
  • Abbvie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Edesa Biotech, Inc.
  • Amgen, Inc.
  • Pfizer Inc.
  • CLINUVEL PHARMACEUTICALS LTD
  • Uniza Group
  • Dr. Reddy's Laboratories Ltd.
  • Roivant Sciences Ltd.
  • Incyte
  • Aclaris Therapeutics, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • GSK plc.
  • Vyne Therapeutics Inc.
  • Temprian Therapeutics Inc.
  • Arrien Pharmaceuticals, LLC

11. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact